Compounding for Patients with Polycystic Ovarian Syndrome (Stein-Leventhal Syndrome)
Author(s): Riepl Mike
Issue: May/Jun 2019 - Volume 23, Number 3
View All Articles in Issue
Page(s): 192-199
Download in electronic PDF format for $65
Abstract: Polycystic ovary syndrome (Stein- Leventhal syndrome) is a common endocrinopathologic condition in reproductive- age women in the U.S. Patients with that disease are not faced with treatment choices for a single medical entity; they must manage a constellation of comorbid conditions that compromise their overall health and diminish their quality of life. The combinations of those disorders are unique to each patient. As a result, the safest and most effective therapeutic approach often requires precision pharmacy: the use of compounded therapies that, unlike commercially manufactured medications, can be precisely adjusted to meet individual needs and modified as therapeutic requirements change. In this article, the manifestations of polycystic ovary syndrome are reviewed, several common concomitant conditions are discussed, therapeutic interventions are suggested, and compounded formulations are provided.
Related Keywords: Mike Riepl, RPh, polycystic ovary syndrome, chronic anovulation, hyperandrogenism, polycystic ovaries, obesity, menstrual dysfunction, insulin resistance, metformin, infertility, hypothalamic-pituitary-adrenal axis, HPA axis, emotional stress, sex hormones, formulations, calcium supplementation, magnesium supplementation, vitamin D3 supplementation, zinc supplementation, hyperinsulinemia, cortisol, dietary recommendations
Related Categories: FORMULATIONS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE